England

Optimising lipid management in people with ASCVD and uncontrolled lipid levels.

Implementing a pharmacist-led initiative with a focus on timely identification and tailored management of ASCVD.

Improve quality of care and early diagnosis of patients with ASCVD.

Establishing an MDT to realise efficiencies in cardiovascular care.

Supporting the MDT with medicines review and optimisation for people with cardiovascular disease.

Providing pathway improvements that lead to better care for people with cardiovascular disease.

Supporting the MDT with medicines review and optimisation for people with ASCVD.

Implementing integrated solutions to improve the detection and treatment of heart failure.

Discover the JWP that aims to provide and implement ongoing remote monitoring and care of disease management in rheumatology.

Funding the implementation of an MRI risk stratification and optimise MRI reviews as a new service model for diagnosing axial psoriatic arthritis.

Find out how the JWP designed a process for engaging with patients remotely to assess their individual needs, and improve access to and experience of care.

Improving the identification and management of suboptimally treated and high-risk people with ASCVD.

Optimising the identification and management of heart failure to deliver improved patient care.

Establishing a pharmacist-led MDT to optimise care for people with ASCVD.

Optimising the identification and management of ASCVD to deliver improved patient care.

Implementing a quality improvement programme to better the care for people with heart failure.

Aiming to improve the overall quality of care and outcomes of metastatic breast cancer patients by implementing metastatic breast cancer multi-disciplinary team.

Establishing a bespoke musculoskeletal ultrasound training programme to facilitate earlier identification of psoriatic arthritis.

Creating an in-house service to optimise treatment for secondary prevention in high-risk ACS.

Establishing workstreams that will help to identify patients and support lipid management in secondary prevention.

Implementing a clinical pharmacist supported by a multidisciplinary health professional team to provide specialty care to high-risk ASCVD patients referred from primary care.

Providing tailored care for people with ASCVD via a GP-led MDT.

Optimising the identification and management of heart failure to deliver improved patient care.

Funding of an additional melanoma and renal cancer clinical nurse specialist to deliver improved patient care.

Implementing innovative clinical tools to improve the time to diagnosis for people affected by ankylosing spondylitis.

Improving lipid management at speed and scale for people with ASCVD.

Improving the quality of care of patients with ASCVD through hiring a full-time band 8a pharmacist and a multidisciplinary team.

Harmonising the screening and assessment of cardiovascular disease across primary care.

Funding of a clinical pharmacist to review and audit patient database to identify sub-optimally treated patients with heart failure and reduced ejection fraction.

Understanding and addressing inequity of access to secondary breast cancer services.

Facilitating remote monitoring to introduce efficiencies in triage and disease management in musculoskeletal services.

Introducing improvements to neurology services via remote solutions.

Implementing digital solutions to capture long COVID outcomes data.

Introducing improvements to rheumatology services via remote solutions.

Introducing efficiencies in care pathways for cardiorenal services.

Aiming to maximise efficiency to optimise workforce in the breast cancer oncology service with a dedicated workforce.

Creating a network for underserved communities at greatest risk of cardiovascular disease and poor health outcomes.

Alleviating burden on cancer services via the funding of a clinical nurse specialist.

Improve quality of care and early identification of patients with ASCVD.

Optimising the identification and management of ASCVD to deliver improved patient care.

Explore the partnership to improve the quality of care for patients and support the early identification, review, and medical optimization of patients with atherosclerotic cardiovascular disease (ASCVD).

Improve the quality and care of patient with ASCVD through early identification, review and medical optimisation.

Recruiting an MS-specific pharmacist to enhance care for people with MS.

Optimising the identification and management of ASCVD to deliver improved patient care.

Improving the quality of care of patients with ASCVD through early identification, review and medical optimisation.

Improve quality of care of patients with ASCVD who are high risk, thorugh medicine optimisation and early identification and review.

Enhancing MS care via the recruitment of an MS co-ordinator to provide non-clinical, patient-focused services.

Modernising the Mobile Macular Unit to improve access to and quality of care.

Redesigning MS service delivery to alleviate capacity and enhance patient care.

Embarking on a series of workshops to refine local lipid pathways.

Updating ophthalmologic services to alleviate capacity and enhance patient access to care.

Implementing a holistic approach to the management of people at risk of cardiovascular disease.

Read about the series of pathway mapping workshops offered by Norvartis as part of a CWP that aims to address local challenges and introduce efficiences.

Improving the quality of care for local ASCVD patients.

Identifying and addressing gaps in primary care for people with ASCVD.

Initiating a nationally scalable, technology-driven approach to identifying people with inherited retinal disease.

Aiming to improve patient backlog management and update the rheumatoid database to improve the quality of rheumatoid services.

Addressing medicines management issues in suboptimally treated ASCVD patients.

Aiming to improve the lipid management system of patients with ASCVD through utilising health search tools and patient review and management systems.

Addressing identification and management issues in at-risk and suboptimally treated ASCVD patients.

Learn about the JWP between Novartis and the Trust to introduce a hospital-based specialist heart failure (HF) service, aiming to improve identification and triaging of patients with HF.

Improve quality of care of patients with ASCVD through early identification, review and medical optimisation.

Improve the quality of care for patients with ASCVD through a multidisciplinary health professional team.

Enhancing the outcomes and experience for people with MS.

Optimising the care pathway for MS via the recruitment of an MS co-ordinator.

Providing additional support to the ASCVD MDT to enhance medicines review and optimisation.

Improve quality of care of patients with diagnosed and undiagnosed ASCVD led by a band 8a pharmacist and a multidisciplinary team.

Embarking on a series of pathway mapping workshops to improve local lipid services.

Supporting the emotional, physical and psychological well-being of HCPs via deployment of a novel app.

Optimising primary care services for people with ASCVD.

Optimising the identification and management of ASCVD to deliver improved patient care.

Optimising the identification and management of ASCVD to deliver improved patient care.

Implement pathway mapping through workshops support to improve patient care and address local challenges.

Improve the quality of care in patients with ASCVD through early identification, review and medical optimisation.

Utilising workshops to implement pathway mapping to support patient care and address local challenges.

Improve the quality of care for patients with ASCVD.

Implementing a new role of cancer therapy clinical nurse specialist supporting the care of patients with metastatic breast cancer who are eligible for systematic anti-cancer therapy.

Utilising workshops to implement pathway mapping to improve efficiency and service effectiveness of patient care and address local challenges.

Implementing local secondary care-led prevention clinic to support the care of secondary prevention patients.

Utilising workshops to implement pathway mapping to improve efficiency and service effectiveness of patient care and address local challenges.

Utilising workshops to implement pathway mapping to improve efficiency and service effectiveness of patient care and address local challenges.

Utilising workshops to implement pathway mapping to improve efficiency and service effectiveness of patient care and address local challenges.

Improve quality of care of patients with ACSVD through implementing an Accelerated Access Collaboration and also implementing a secondary care-led secondary prevention clinic.

Improve quality of care and early diagnosis of patients with ASCVD.

Utilising workshops to implement pathway mapping to improve efficiency and service effectiveness of patient care and address local challenges.